Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT06099093 Not yet recruiting - Prostate Cancer Clinical Trials

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Start date: April 2024
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).

NCT ID: NCT06062355 Not yet recruiting - Prostate Cancer Clinical Trials

Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer

Start date: October 2023
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry of HRS-9815 for PET/CT imaging in adult patients with prostate cancer.

NCT ID: NCT06034431 Not yet recruiting - Prostate Cancer Clinical Trials

Increasing Access to Definitive Treatment for Prostate Cancer

Start date: September 2023
Phase: N/A
Study type: Interventional

Investigators will address the overarching challenge of advancing health equity and reducing disparities in prostate cancer by informing efforts to reduce travel burden in prostate cancer (PCa) treatment access among Black men.

NCT ID: NCT05989854 Not yet recruiting - Prostate Cancer Clinical Trials

The Remote Study: Investigating the Effects or Online Exercise on Quality of Life in Men With Prostate Cancer

Start date: October 2023
Phase: N/A
Study type: Interventional

Currently, there are few opportunities for patients with cancer to have individual exercise guidance, and this has further been impacted by the Covid-19 pandemic. However, during the pandemic the use of virtual/remote platforms has been crucial in delivering care to cancer patients. The investigators think that remote exercise training may also offer a solution to support positive change in prostate cancer patients. As a result, the investigators have developed a remote/online exercise programme to explore this further. This study will explore the effectiveness of an 8-week remote exercise and behavioural support intervention, and whether prostate cancer patients feel they benefit from this. The study also aims to see if this sort of exercise programme can be delivered to more prostate cancer patients in the future. This project is open to men with prostate cancer on long term hormone therapy. The intervention will be comprised of one remote supervised session per week, completed 1-1 using an online platform and up to two additional sessions, depending on its suitability for the patient, will be prescribed as unsupervised home-based exercise.

NCT ID: NCT05982418 Not yet recruiting - Prostate Cancer Clinical Trials

Improvement of RARP Outcomes Via 3D Printed/Virtual Prostate Models

RARP-3D
Start date: July 31, 2023
Phase: N/A
Study type: Interventional

Study the effect 3D printed or 3D virtual prostate models of a patient, when manipulated by surgeons during RARP, has on positive surgical margins and functional outcomes of patients. Our main hypothesis is that there is a reduction of positive resection margins and functional outcomes of patients undergoing RARP when surgeons are presented with 3D printed or 3D virtual patient-specific prostate models during surgery. Specifically, we hypothesize that the anatomical knowledge of surgeons that results from the manipulation of 3D printed/virtual models constructed from automated segmentations reduces positive resection margins and functional outcomes.

NCT ID: NCT05978232 Not yet recruiting - Breast Cancer Clinical Trials

NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

African-Americans have disparately limited access to optimal cancer care. They have the highest overall cancer death rate and shortest survival time of any racial or ethnic group in the United States. Elucidation of disparities in access to cancer care are important since previous work has indicated that when equal access to RT in Radiation Therapy Oncology Group (RTOG) prospective randomized trials is granted, race does not independently affect outcomes, a finding similar to work conducted in Level I evidence-proven optimal management of curable neurologic conditions. Breast cancer is the most common cancer in African-American women and Prostate cancer is the most common cancer in African-American men. African-American breast & prostate cancer participants are less likely to receive standard-of-care radiation therapy. Previous work has identified that compared to Caucasian women with breast cancer, African-American women are 48% more likely to have RT omission during treatment, 167% less likely to receive timely completion of RT after breast-conserving surgery, 40% less likely to complete RT, and significantly more likely to experience RT treatment delays. Shorter course radiation therapy may reduce disparities in radiation therapy care facing African-American breast cancer participants.

NCT ID: NCT05974774 Not yet recruiting - Prostate Cancer Clinical Trials

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

Start date: June 15, 2024
Phase: Phase 3
Study type: Interventional

This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce resource utilization. The primary goal of de-escalation is to investigate whether using an intermittent regime results in a similar OS to continuous treatment.

NCT ID: NCT05973149 Not yet recruiting - Prostate Cancer Clinical Trials

Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Start date: August 31, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer

NCT ID: NCT05958082 Not yet recruiting - Prostate Cancer Clinical Trials

Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer

Start date: June 2024
Phase: N/A
Study type: Interventional

This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.

NCT ID: NCT05957653 Not yet recruiting - Prostate Cancer Clinical Trials

Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort

Start date: October 7, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to evaluate the incidence and severity of postoperative catheter-related bladder discomfort after robot-assisted radical prostatectomy. The main question it aims to answer is to evaluate incidence of CRBD immediately after extubation in resuscitation. A total of 20ml of 2% lidocaine and 1μg/ml sufentanil or 20ml normal saline was injected into the bladder of the participants through the catheter. After drug injection, the catheter was clamped for 20 minutes, and then 100ml normal saline was injected into the bladder through the catheter to flush out. Then, the incidence of CRBD was compared between the two groups.